Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,166 GBX | -0.05% | -1.35% | +14.77% |
May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
May. 16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.77% | 239B | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B | |
+0.45% | 163B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication